Nutriband (NTRB) Expands Kinesiology Tape Production and Advance

Nutriband (NTRB, Financial) is enhancing its production capabilities through its subsidiary, Pocono Pharma, to increase its share in the kinesiology tape market. The company employs penetration pricing to establish a presence among major industry players. In the first quarter, Nutriband reported a significant revenue increase, reaching $667,000, which marks a 63% year-over-year growth. Pocono Pharma's products are now available at well-known retailers across the United States, including Target, Walmart, Walgreens, and CVS, contributing significantly to Nutriband's revenue growth and shareholder value.

In addition to expanding product lines, Nutriband is making notable progress with its AVERSA Fentanyl development. They have formalized a strategic partnership with Kindeva Drug Delivery to manage product development costs through milestone payments. This collaboration aims to advance Nutriband's transdermal drug delivery innovations towards regulatory approval and market introduction. Notably, AVERSA Fentanyl is designed as the first abuse-deterrent opioid patch to prevent misuse and accidental exposure. It has the potential to achieve peak annual sales in the U.S. ranging from $80 million to $200 million.

Based on the one-year price targets offered by 1 analysts, the average target price for Nutriband Inc (NTRB, Financial) is $13.00 with a high estimate of $13.00 and a low estimate of $13.00. The average target implies an upside of 100.00% from the current price of $6.50. More detailed estimate data can be found on the Nutriband Inc (NTRB) Forecast page.

Based on the consensus recommendation from 1 brokerage firms, Nutriband Inc's (NTRB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Nutriband Inc (NTRB, Financial) in one year is $3.85, suggesting a downside of 40.77% from the current price of $6.5. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Nutriband Inc (NTRB) Summary page.

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!